Management of Neuropsychiatric Symptoms in Long-Term Care Residents with Parkinson’s Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The management of neuropsychiatric symptoms, including psychosis, in Parkinson’s Disease (PD) is complicated by the fact that treatment with antipsychotics can worsen the movement disorder, which may necessitate changes to antiparkinsonian medications.
The objectives of this study were to determine what antipsychotics are prescribed to residents in long-term care with PD and document subsequent changes in levodopa dosage.
A retrospective cohort study using administrative health database information from Ontario, Canada, was conducted. PD diagnostic codes were obtained from the Ontario Health Insurance Plan (physician diagnostic codes) and the Canadian Institute of Health Information (hospitalization discharge diagnoses). The Ontario Drug Benefit database provided information on the use of antiparkinsonian medications and antipsychotics. Residents diagnosed with PD in long-term care were included if they were treated with stable doses of levodopa monotherapy and received a new prescription for an antipsychotic. The type of antipsychotic and the changes in levodopa dosage were determined.
There were 479 residents who met inclusion criteria. The prescribed antipsychotics were quetiapine (n = 192; 40 %), risperidone (n = 185; 39 %) and olanzapine (n = 81; 17 %), and only 21 (4 %) received a prescription for a typical antipsychotic. The first levodopa dosage change was a dose reduction in 469 (98 %) patients, and a dose increase in ten (2 %) patients.
Many PD patients in long-term care are treated with potentially inappropriate antipsychotic medications. However, there is no evidence that this treatment results in a prescribing cascade that leads to inappropriate increases in levodopa dosage.
- Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56:S1–88. CrossRef
- Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson’s disease. CMAJ. 2006;175:1545–52.
- Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson’s disease: from description to etiology. J Neurol. 2005;252:753–64. CrossRef
- Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–45. CrossRef
- Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52:784–8. CrossRef
- Aarsland D, Larsen JP, Tandberg E. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938.
- Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002. CrossRef
- Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165–71. CrossRef
- Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26:S42–80. CrossRef
- Weintraub D, Chen P, Ignacio RV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;88:899–904. CrossRef
- Wang M-T, Lian P-W, Yeh C-B, et al. Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson’s disease. Mov Disord. 2011;26:1663–9. CrossRef
- Gruneir A, Anderson GM, Rochon PA, Bronskill S. Transitions in long-term care and potential implications for quality reporting in Ontario, Canada. J Am Med Dir Assoc. 2010;11:629–35. CrossRef
- Group TFCPS. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999;353:2041–2. CrossRef
- No authors listed. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med. 1999;340:757–63. CrossRef
- Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356–63. CrossRef
- Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–32. CrossRef
- Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882–8. CrossRef
- Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633–7. CrossRef
- Herrmann N, Lanctot KL. Pharmacological management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry. 2007;52:630–46.
- Marras C, Gruneir A, Wang X, et al. Antipsychotics and mortality in parkinsonism. Am Journal Geriatr Psychiatry. 2012;20:149–58. CrossRef
- Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21:1899–907. CrossRef
- Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–77. CrossRef
- Management of Neuropsychiatric Symptoms in Long-Term Care Residents with Parkinson’s Disease
Drugs & Aging
Volume 30, Issue 1 , pp 19-22
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
- 2. Toronto Western Hospital Movement Disorders Centre, University of Toronto and the Edmond J. Safra Program in Parkinson’s Research, Toronto, ON, Canada
- 3. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
- 4. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- 5. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada
- 6. Department of Medicine, University of Toronto, Toronto, ON, Canada